Skip to content

Publications

Acknowledgement

Science Foundation Ireland for financial support

M2i for providing technical advice and discounted academic rates for FDG

We would like to thank the co-authors of the listed reference studies for their technical and other assistance.

 

Example Publications Taking Advantage of IVIS Spectrum, microCT and PET CT   at UCD:

A Novel Positron Emission Tomography (PET) Approach to Monitor Cardiac Metabolic Pathway Remodeling in Response to Sunitinib Malate.

O’Farrell AC, Evans R, Silvola JM, Miller IS, Conroy E, Hector S, Cary M, Murray DW, Jarzabek MA, Maratha A, Alamanou M, Udupi GM, Shiels L, Pallaud C, Saraste A, Liljenbäck H, Jauhiainen M, Oikonen V, Ducret A, Cutler P, McAuliffe FM, Rousseau JA, Lecomte R, Gascon S, Arany Z, Ky B, Force T, Knuuti J, Gallagher WM, Roivainen A, Byrne AT.

PLoS One. 2017 Jan 27;12(1):e0169964. doi: 10.1371/journal.pone.0169964.

PMID: 28129334 Free PMC Article

________________________________________________________________________________________________________________________

Patterns of orofacial clefting in the facial morphology of bats: a possible naturally occurring model of cleft palate.

Orr DJ, Teeling EC, Puechmaille SJ, Finarelli JA.

J Anat. 2016 Nov;229(5):657-672. doi: 10.1111/joa.12510.

PMID: 27346883

________________________________________________________________________________________________________________________

Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer.

Murphy AG, Casey R, Maguire A, Tosetto M, Butler CT, Conroy E, Reynolds AL, Sheahan K, O’Donoghue D, Gallagher WM, Fennelly D, Kennedy BN, O’Sullivan J.

Sci Rep. 2016 Oct 14;6:34523. doi: 10.1038/srep34523.

PMID: 27739445 Free PMC Article

________________________________________________________________________________________________________________________

Lysosome triggered near-infrared fluorescence imaging of cellular trafficking processes in real time.

Grossi M, Morgunova M, Cheung S, Scholz D, Conroy E, Terrile M, Panarella A, Simpson JC, Gallagher WM, O’Shea DF.

Nat Commun. 2016 Mar 1;7:10855. doi: 10.1038/ncomms10855.

PMID: 26927507 Free PMC Article

________________________________________________________________________________________________________________________

Small field detector correction factors kQclin,Qmsr (fclin,fmsr) for silicon-diode and diamond detectors with circular 6 MV fields derived using both empirical and numerical methods.

O’Brien DJ, León-Vintró L, McClean B.

Med Phys. 2016 Jan;43(1):411. doi: 10.1118/1.4938584.

PMID: 26745934

________________________________________________________________________________________________________________________

Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models.

Jarzabek MA, Amberger-Murphy V, Callanan JJ, Gao C, Zagozdzon AM, Shiels L, Wang J, Ligon KL, Rich BE, Dicker P, Gallagher WM, Prehn JH, Byrne AT.

Br J Cancer. 2014 Dec 9;111(12):2275-86. doi: 10.1038/bjc.2014.529.

PMID: 25375271 Free PMC Article

________________________________________________________________________________________________________________________

Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors.

Rani S, Corcoran C, Shiels L, Germano S, Breslin S, Madden S, McDermott MS, Browne BC, O’Donovan N, Crown J, Gogarty M, Byrne AT, O’Driscoll L.

Cancer Res. 2014 Jul 15;74(14):3821-33. doi: 10.1158/0008-5472.CAN-13-2053.

PMID: 24876102 Free Article

________________________________________________________________________________________________________________________

Generation of a new bioluminescent model for visualisation of mammary tumour development in transgenic mice.

Zagozdzon AM, O’Leary P, Callanan JJ, Crown J, Gallagher WM, Zagozdzon R.

BMC Cancer. 2012 May 30;12:209. doi: 10.1186/1471-2407-12-209. PMID: 22646761 [PubMed – indexed for MEDLINE] Related citations

________________________________________________________________________________________________________________________

Mechanism of cell death mediated by a BF2-chelated tetraaryl-azadipyrromethene photodynamic therapeutic: dissection of the apoptotic pathway in vitro and in vivo.

O’Connor AE, Mc Gee MM, Likar Y, Ponomarev V, Callanan JJ, O’shea DF, Byrne AT, Gallagher WM.

Int J Cancer. 2012 Feb 1;130(3):705-15. doi: 10.1002/ijc.26073.

PMID: 21413012 Free Article

________________________________________________________________________________________________________________________

Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.

O’Donovan N, Byrne AT, O’Connor AE, McGee S, Gallagher WM, Crown J.

Invest New Drugs. 2011 Oct;29(5):752-9. doi: 10.1007/s10637-010-9415-5.

PMID: 20229355

________________________________________________________________________________________________________________________

The hydroxylase inhibitor dimethyloxallyl glycine attenuates endotoxic shock via alternative activation of macrophages and IL-10 production by b1 cells.

Hams E, Saunders SP, Cummins EP, O’Connor A, Tambuwala MT, Gallagher WM, Byrne A, Campos-Torres A, Moynagh PM, Jobin C, Taylor CT, Fallon PG.

Shock. 2011 Sep;36(3):295-302. PMID: 21844787 [PubMed – in process] Related citations

________________________________________________________________________________________________________________________

An intact canonical NF-κB pathway is required for inflammatory gene expression in response to hypoxia.

Fitzpatrick SF, Tambuwala MM, Bruning U, Schaible B, Scholz CC, Byrne A, O’Connor A, Gallagher WM, Lenihan CR, Garvey JF, Howell K, Fallon PG, Cummins EP, Taylor CT.

J Immunol. 2011 Jan 15;186(2):1091-6. doi: 10.4049/jimmunol.1002256.

PMID: 21149600 Free Article

________________________________________________________________________________________________________________________

Bioluminescent imaging: a critical tool in pre-clinical oncology research.

O’Neill K, Lyons SK, Gallagher WM, Curran KM, Byrne AT.

J Pathol. 2010 Feb;220(3):317-27. doi: 10.1002/path.2656. Review.

PMID: 19967724

________________________________________________________________________________________________________________________

Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies.

van der Meel R, Gallagher WM, Oliveira S, O’Connor AE, Schiffelers RM, Byrne AT.

Drug Discov Today. 2010 Feb;15(3-4):102-14. doi: 10.1016/j.drudis.2009.12.003. Review.

PMID: 20035896

________________________________________________________________________________________________________________________

Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment.

Byrne AT, O’Connor AE, Hall M, Murtagh J, O’Neill K, Curran KM, Mongrain K, Rousseau JA, Lecomte R, McGee S, Callanan JJ, O’Shea DF, Gallagher WM.

Br J Cancer. 2009 Nov 3;101(9):1565-73. doi: 10.1038/sj.bjc.6605247.

PMID: 19826417  Free PMC Article

________________________________________________________________________________________________________________________

Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinical advances in photodynamic therapy.

O’Connor AE, Gallagher WM, Byrne AT.

Photochem Photobiol. 2009 Sep-Oct;85(5):1053-74. doi: 10.1111/j.1751-1097.2009.00585.x. Review.

PMID: 19682322